粪钙卫蛋白检测市场 - 全球产业规模、份额、趋势、机会及预测（按检测类型、适应症、最终用户、地区和竞争格局划分，2021-2031年）

全球粪便钙卫蛋白检测市场预计将从 2025 年的 3.531 亿美元成长到 2031 年的 5.3021 亿美元，复合年增长率为 7.01%。

这个市场的核心是非侵入性诊断免疫检测，它透过测量粪便中存在的中性粒细胞蛋白质——钙卫蛋白来识别肠道发炎。这项检测主要用于区分嗜中性白血球(IBD) 和功能性胃肠疾病，例如大肠激躁症(IBS)。市场成长的主要驱动因素是 IBD 盛行率的不断上升，以及临床上减少不必要的侵入性检查（例如大肠镜检查）的趋势，这些趋势提高了患者的依从性并增强了成本效益。加拿大克隆氏症症和结肠炎协会估计，到 2025 年，发炎性肠道疾病在加拿大的盛行率将达到 0.8%，这凸显了可靠疾病监测的必要性。

然而，商业生产商之间检测方法缺乏标准化，对市场扩张构成重大挑战。不同检测套组在分析性能和验收基准值上的差异，常常导致结果不一致，使临床医生难以解读数据，并阻碍了通用参考范围的建立，而通用参考范围对于患者照护至关重要。这种差异性造成了结果互换性的不确定性，并可能延缓检测方法被接受为疾病活动监测金标准的进程。

市场驱动因素

全球发炎性肠道疾病 (IBD) 盛行率的上升是推动全球粪钙卫蛋白检测市场成长的主要因素。克隆氏症和溃疡性大肠炎等慢性疾病盛行率的增加，导致人们对可靠、非侵入性的监测工具的需求激增，这些工具能够有效管理长期发炎并预防復发。根据美国疾病管制与预防中心 (CDC) 于 2024 年 6 月发布的《IBD 事实与统计》报告，美国 IBD 患者人数估计在 240 万至 310 万之间。不断增长的患者群体需要频繁进行检测，以区分活动性发炎和功能性疾病，这推动了对钙卫蛋白检测的需求成长。国际上也出现了类似的趋势：根据英国克隆氏症症和结肠炎协会 2024 年的报告，英国约有 50 万人患有 IBD，这凸显了可扩展诊断解决方案的必要性。

随着这项需求的成长，居家检测和照护现场盒的技术进步正透过提高检体稳定性和提升患者便利性来改变市场格局。儘管粪便检体在运输过程中保存的物流挑战历来阻碍了远端监测的广泛应用，但缓衝液稳定性的最新改进正在逐步解决这些障碍。例如，Sentinel Diagnostics公司于2024年11月宣布，其CALiAGold Pierce Tubes试管新增一项功能，可让患者在分析前将检体在室温下保存长达四周。此类创新透过简化检体采集流程、促进在临床环境之外进行持续的疾病监测以及加速需要终身管理的患者的市场渗透，显着提高了患者的依从性。

市场挑战

商业厂商之间缺乏标准化的检测方法是全球粪便钙卫蛋白检测市场成长的主要障碍。不同的检测套组通常采用不同的抗体和捕获方法，导致同一患者检体的定量结果和临界值有差异。这种分析变异性使临床解读变得复杂，医疗机构难以确定通用的参考范围，也难以比较不同检测平台的数据。因此，临床医生仍不愿完全依赖这些免疫检测进行患者后续观察，阻碍了该诊断工具在常规医疗实践中的广泛应用。

这种不一致直接阻碍了市场扩充性的扩大，尤其是在对可靠的慢性病管理需求庞大的情况下。根据克隆氏症和结肠炎基金会2024年的预测，约有300万美国人患有发炎性肠道疾病，这是一个庞大的患者群体，需要频繁进行发炎监测。然而，不同製造商之间检测结果无法协调一致，造成了营运瓶颈。如果检测数据无法在不同检查室间互通，医疗系统不太可能全面采用这些检测方法，从而限制了这些诊断产品的收入潜力和整体市场渗透率。

市场趋势

随着临床检查室从手动方法转向整合平台以应对日益增长的检体量，市场正经历着向自动化高通量检查室免疫检测的转变。传统的酵素免疫分析法(ELISA) 正被可在标准临床化学分析仪上运行的颗粒增强浊度免疫检测(PETIA) 所取代，从而实现随机访问检测并显着缩短结果週转时间。这种自动化使诊断机构能够有效地扩展业务规模，以满足不断增长的胃肠道检测需求。例如，Sysmex America 于 2025 年 1 月宣布与加拿大达成 Sentinel Diagnostics SENTiFIT 800 分析仪的经销协议。这款高速系统每小时可处理多达 550 个检体，从而实现大通量检体分析。

同时，市场正在拓展其在「纵向治疗监测」和「黏膜癒合评估」方面的应用，超越了此检测最初区分发炎性肠道疾病（IBD）和肠躁症（IBS）的功能。临床医生正在采用「目标导向治疗」策略，利用频繁的粪钙卫蛋白检测作为一种非侵入性手段，取代内视镜检查，以评估已确诊患者的治疗反应和黏膜发炎情况。这种临床转变得益于旨在支持定期疾病后续观察的医保报销体系的不断发展。例如，《边缘系统》（The Limbic）在2025年10月报道称，澳洲政府推出了一项新的医疗保险项目编号，用于支持在已确诊炎症性肠病（IBD）症状患者的持续管理中进行钙卫蛋白检测，这反映了全球对该检测在长期护理中价值的认可。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球粪便钙卫蛋白检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依检测类型（酵素免疫分析法（ELISA）、酵素萤光免疫分析、定量层析法）
  • 依适应症（发炎性肠道疾病 (IBD) 诊断、结肠癌、乳糜泻、其他）
  • 依最终使用者（医院、诊断检查室、学术研究机构等）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美粪便钙卫蛋白检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲粪便钙卫蛋白检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区粪便钙卫蛋白检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲粪便钙卫蛋白检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲粪便钙卫蛋白检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球粪钙卫蛋白检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd
• Boditech Med Inc.
• Abbexa Ltd.
• Elabscience Bionovation Inc.
• Epitope Diagnostics, Inc.
• R-Biopharm AG
• Sentinel Ch SpA
• LifeSpan BioSciences, Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Fecal Calprotectin Test Market is projected to increase from USD 353.10 Million in 2025 to USD 530.21 Million by 2031, expanding at a CAGR of 7.01%. This market centers on a non-invasive diagnostic immunoassay that measures calprotectin, a neutrophilic protein present in stool, to identify intestinal inflammation. The test is primarily employed to distinguish between Inflammatory Bowel Disease (IBD) and functional gastrointestinal disorders like Irritable Bowel Syndrome (IBS). Growth is largely driven by the rising prevalence of IBD and a clinical shift toward reducing unnecessary invasive procedures, such as colonoscopies, which improves patient compliance and cost-efficiency. Underscoring the need for reliable disease monitoring, Crohn's and Colitis Canada estimates that the prevalence of Inflammatory Bowel Disease will reach 0.8% of the Canadian population in 2025.

However, the lack of assay standardization across commercial manufacturers presents a significant challenge to broader market expansion. Differences in analytical performance and cut-off values among various test kits often result in inconsistent findings, complicating data interpretation for clinicians and preventing the creation of universal reference ranges essential for long-term patient care. This variability generates uncertainty regarding the interchangeability of results, potentially delaying the acceptance of these tests as the primary standard for monitoring disease activity.

Market Driver

The rising global incidence of Inflammatory Bowel Diseases (IBD) acts as a primary catalyst for the growth of the Global Fecal Calprotectin Test Market. As chronic conditions like Crohn's disease and ulcerative colitis become more widespread, there is a surging demand for reliable, non-invasive monitoring tools to effectively manage long-term inflammation and prevent relapses. The Centers for Disease Control and Prevention's 'IBD Facts and Stats' report from June 2024 estimated that between 2.4 and 3.1 million individuals in the United States have IBD. This growing patient population requires frequent testing to differentiate active inflammation from functional disorders, thereby fueling the consumption of calprotectin assays. This trend is further supported internationally, with Crohn's & Colitis UK reporting in 2024 that approximately 500,000 people in the United Kingdom live with IBD, highlighting the need for scalable diagnostic solutions.

Concurrent with this demand, technological advancements in home-testing and point-of-care kits are reshaping the market by improving sample stability and patient convenience. Historically, logistical difficulties in preserving fecal samples during transport hindered the adoption of remote monitoring, but recent improvements in buffer stability have addressed these barriers. For example, Sentinel Diagnostics announced in November 2024 the capabilities of its new CALiaGold pierce Tube, which allows patients to store samples at room temperature for up to four weeks before analysis. Such innovations significantly enhance compliance by simplifying the collection process, facilitating consistent disease monitoring outside clinical settings, and accelerating market penetration for patients requiring lifelong management.

Market Challenge

The absence of assay standardization among commercial manufacturers constitutes a major barrier to the Global Fecal Calprotectin Test Market's growth. Because different test kits frequently employ distinct antibodies and capture methods, they often yield inconsistent quantitative results and cut-off values for identical patient samples. This analytical variability complicates clinical interpretation, making it challenging for healthcare providers to define universal reference ranges or compare data across different testing platforms. Consequently, clinicians remain hesitant to rely exclusively on these immunoassays for longitudinal patient monitoring, which limits the widespread integration of this diagnostic tool into routine medical practice.

This inconsistency directly impedes market scalability, particularly given the critical demand for reliable chronic disease management. With the Crohn's & Colitis Foundation estimating in 2024 that approximately 3 million Americans are affected by Inflammatory Bowel Disease, a substantial patient population requires frequent inflammation monitoring. However, the inability to harmonize results across different manufacturers creates an operational bottleneck. Healthcare systems are unlikely to fully commit to a testing modality where data cannot be interchanged between laboratories, thereby restricting the revenue potential and overall market penetration of these diagnostic products.

Market Trends

The market is being transformed by a shift toward Automated High-Throughput Laboratory Immunoassays as clinical laboratories move from manual methods to integrated platforms to manage increasing sample volumes. Traditional Enzyme-Linked Immunosorbent Assays (ELISA) are being replaced by particle-enhanced turbidimetric immunoassays (PETIA) that operate on standard clinical chemistry analyzers, allowing for random-access testing and significantly reduced turnaround times. This automation enables diagnostic facilities to scale operations efficiently to meet the rising demand for gastrointestinal testing. Illustrating this advancement, Sysmex America announced in January 2025 an agreement to distribute the Sentinel Diagnostics SENTiFIT 800 Analyzer in Canada, a high-speed system capable of processing up to 550 tests per hour to handle mass-volume analysis.

Simultaneously, the market is seeing increasing utilization for Longitudinal Treatment Monitoring and Mucosal Healing, expanding beyond the test's original role of distinguishing IBD from IBS. Clinicians are adopting "treat-to-target" strategies that use frequent fecal calprotectin measurements as a non-invasive surrogate for endoscopy to assess therapeutic response and mucosal inflammation in established patients. This clinical shift is validated by evolving reimbursement structures aimed at supporting regular disease tracking. For instance, The Limbic reported in October 2025 that the Australian government introduced a new Medicare item number to subsidize calprotectin testing for the ongoing management of symptomatic patients with an established IBD diagnosis, reflecting global recognition of the test's value in long-term care.

Key Market Players

• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd
• Boditech Med Inc.
• Abbexa Ltd.
• Elabscience Bionovation Inc.
• Epitope Diagnostics, Inc.
• R-Biopharm AG
• Sentinel Ch S.p.A.
• LifeSpan BioSciences, Inc

Report Scope

In this report, the Global Fecal Calprotectin Test Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fecal Calprotectin Test Market, By Assay Type

• Enzyme Linked Immunosorbent Assay (ELISA)
• Enzyme Fluoroimmunoassay
• Quantitative Immune-Chromatography

Fecal Calprotectin Test Market, By Indication

• Inflammatory Bowel Disease (IBD) Diagnosis
• Colorectal Cancer
• Celiac Disease
• others

Fecal Calprotectin Test Market, By End User

• Hospitals
• Diagnostic Laboratories
• Academic and Research Institutes
• others

Fecal Calprotectin Test Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Fecal Calprotectin Test Market.

Available Customizations:

Global Fecal Calprotectin Test Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Fecal Calprotectin Test Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Assay Type (Enzyme Linked Immunosorbent Assay (ELISA), Enzyme Fluoroimmunoassay, Quantitative Immune-Chromatography)
  • 5.2.2. By Indication (Inflammatory Bowel Disease (IBD) Diagnosis, Colorectal Cancer, Celiac Disease, others)
  • 5.2.3. By End User (Hospitals, Diagnostic Laboratories, Academic and Research Institutes, others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Fecal Calprotectin Test Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Assay Type
  • 6.2.2. By Indication
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Fecal Calprotectin Test Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Assay Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Fecal Calprotectin Test Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Assay Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Fecal Calprotectin Test Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Assay Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By End User

7. Europe Fecal Calprotectin Test Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Assay Type
  • 7.2.2. By Indication
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Fecal Calprotectin Test Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Assay Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By End User
  • 7.3.2. France Fecal Calprotectin Test Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Assay Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Fecal Calprotectin Test Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Assay Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Fecal Calprotectin Test Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Assay Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Fecal Calprotectin Test Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Assay Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By End User

8. Asia Pacific Fecal Calprotectin Test Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Assay Type
  • 8.2.2. By Indication
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Fecal Calprotectin Test Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Assay Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By End User
  • 8.3.2. India Fecal Calprotectin Test Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Assay Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Fecal Calprotectin Test Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Assay Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Fecal Calprotectin Test Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Assay Type
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Fecal Calprotectin Test Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Assay Type
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By End User

9. Middle East & Africa Fecal Calprotectin Test Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Assay Type
  • 9.2.2. By Indication
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Fecal Calprotectin Test Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Assay Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Fecal Calprotectin Test Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Assay Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Fecal Calprotectin Test Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Assay Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By End User

10. South America Fecal Calprotectin Test Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Assay Type
  • 10.2.2. By Indication
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Fecal Calprotectin Test Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Assay Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Fecal Calprotectin Test Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Assay Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Fecal Calprotectin Test Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Assay Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Fecal Calprotectin Test Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bio-Rad Laboratories, Inc.
• 15.3. F. Hoffmann-La Roche Ltd
• 15.4. Boditech Med Inc.
• 15.5. Abbexa Ltd.
• 15.6. Elabscience Bionovation Inc.
• 15.7. Epitope Diagnostics, Inc.
• 15.8. R-Biopharm AG
• 15.9. Sentinel Ch S.p.A.
• 15.10. LifeSpan BioSciences, Inc

16. Strategic Recommendations

17. About Us & Disclaimer